Cargando…

The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases

Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process...

Descripción completa

Detalles Bibliográficos
Autor principal: Glass, Jonathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Dana Foundation 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574778/
https://www.ncbi.nlm.nih.gov/pubmed/23447769
_version_ 1782259636623114240
author Glass, Jonathan D.
author_facet Glass, Jonathan D.
author_sort Glass, Jonathan D.
collection PubMed
description Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process necessary to determine whether stem-cell treatments are safe and effective, meaning that the benefits—if there prove to be any—outweigh the risks. But even as FDA-approved trials are underway, some people with neurodegenerative disorders are turning to dangerous, unapproved stem-cell treatments out of desperation. Dr. Glass warns that researchers must strictly adhere to the scientific process in order to convert the hope of stem-cell treatments into reality.
format Online
Article
Text
id pubmed-3574778
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The Dana Foundation
record_format MEDLINE/PubMed
spelling pubmed-35747782013-02-27 The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases Glass, Jonathan D. Cerebrum Article Jonathan D. Glass, M.D., is leading a clinical trial testing the safety of using adult stem cells to treat patients with amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that remains untreatable. This trial, along with others like it, is just the beginning of a time-intensive process necessary to determine whether stem-cell treatments are safe and effective, meaning that the benefits—if there prove to be any—outweigh the risks. But even as FDA-approved trials are underway, some people with neurodegenerative disorders are turning to dangerous, unapproved stem-cell treatments out of desperation. Dr. Glass warns that researchers must strictly adhere to the scientific process in order to convert the hope of stem-cell treatments into reality. The Dana Foundation 2010-12-15 /pmc/articles/PMC3574778/ /pubmed/23447769 Text en Copyright 2010 The Dana Foundation All Rights Reserved
spellingShingle Article
Glass, Jonathan D.
The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title_full The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title_fullStr The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title_full_unstemmed The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title_short The Promise and the Reality of Stem-Cell Therapies for Neurodegenerative Diseases
title_sort promise and the reality of stem-cell therapies for neurodegenerative diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574778/
https://www.ncbi.nlm.nih.gov/pubmed/23447769
work_keys_str_mv AT glassjonathand thepromiseandtherealityofstemcelltherapiesforneurodegenerativediseases
AT glassjonathand promiseandtherealityofstemcelltherapiesforneurodegenerativediseases